Key facts
- This page summarizes Ben Bronstein's Form 4 filing for Aldeyra Therapeutics, Inc. (ALDX).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 10 Jun 2021, 17:44.
Ben Bronstein - 08 Jun 2021 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)
- Reporting relationship
- Director
- Issuer ticker
- ALDX
- Reported as of
- 08 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2021, 17:44:58 UTC
- Next SEC filing
- 09 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ben Bronstein
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ben Bronstein filed Form 4 for Aldeyra Therapeutics, Inc. (ALDX) on 10 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALDX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,534
- Change %
- Price
- $0.000000
- Shares after
- 13,534
- Date
- 08 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,534
- Exercise price
- $12.97
- Footnotes
- F1
ALDX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +875
- Change %
- Price
- $0.000000
- Shares after
- 875
- Date
- 08 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 875
- Exercise price
- $12.97
- Footnotes
- F2
ALDX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +933
- Change %
- Price
- $0.000000
- Shares after
- 933
- Date
- 08 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 933
- Exercise price
- $12.97
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
Footnote F2
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
Footnote F3
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.